Immunoliposomes carrying plasmid DNA: preparation and characterization

Bailey, A. L. and Sullivan, S. M., Efficient encapsulation of DNA plasmids in small neutral liposomes induced by ethanol and calcium.Biochim. Biophys. Acta, 1468, 239–252 (2000).

Boris-Lawrie, K. A. and Temin, H. M., Recent advances in retrovirus vector technology.Curr. Opin. Genet. Dev., 3, 102–109 (1993).

Harrison, G. S., Wang, Y., Tomezak, J., Hogan, C., Shpall, E. J., Curiel, T. J., and Feigner, P. L., Optimization of gene transfer using cationic lipids in cell lines and primary human CD4+and CD34 hematopoietic cells.Biotechniques, 19, 816–823 (1995).

Huwyler, J., Dafang, W., and Pardridge, W. M., Brain drug delivery of small molecules using immunoliposomes.Proc. Natl. Acad. Sci. U.S.A., 93, 14164–14169 (1996).

Lamb, B. T., Sisodia, S. S., Lawler, A. M., Slunt, H. H., Kitt, C. A., Kearns, W. G., Pearson, P. L., Price, D. L., and Gearhart, J. D., Introduction and expression of the 400 kilobase precursor amyloid protein gene in transgenic mice.Nature Genet., 5, 22–30 (1993).

Li, S. and Huang, L.,In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes.Gene Ther., 4, 891–900 (1997).

Li, S. and Huang, L., Nonviral gene therapy: promises and challenges.Gene Ther., 7, 31–34 (2000).

Mamot, C., Drummond, D. C., Greiser, U., Hong, K., Kirpotin, D. B., Marks, J. D., and Park, J. W., Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediated specific and efficient drug delivery to EGFR- and EGFRvlll-overexpressing tumor cells.Cancer Res., 63, 3154–3161 (2003).

Maruyama, K., Ishida, O., Takizawa, T., and Moribe, K., Possibility of active targeting to tumor tissues with liposomes.Adv. Drug Deliv. Rev., 40, 89–102 (1999).

Miller, A. D., Retroviral vectors.Curr. Top. Microbiol. Immunol., 158, 1–24 (1992).

Monnard, P.-A., Oberholzer, T., and Luisi, P. L., Entrapment of nucleic acids in liposomes.Biochim. Biophys. Acta, 1329, 39–50 (1997).

Nabel, G. J., Nabel, E. G., Yang, Z.-Y., Fox, B. A., Plautz, G. E., Gao, X., Huang, L., Shu, S., Gordon, D., and Chang, A. E., Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity and lack of toxicity in humans.Proc. Natl. Acad. Sci. U.S.A., 90, 11307–11311 (1993).

Pardridge, W. M., Buciak, J. L., and Yoshikawa, T., Transport of recombinant CD4 through the rat blood-brain barrierin vivo.J. Pharmacol. Exp. Ther., 261, 1175–1180 (1992).

Park, H. M., Chung, S. Y., Go, E. J., and Lee, H. J., Preparation and characterization of plasmid DNA encapsulated in liposomes.J. Kor. Pharm. Sci., 33, 209–213 (2003).

Pastorino, F., Stuart, D., Ponzoni, M., and Allen, T. M., Targeted delivery of antisense oligonucleotides in cancer.J. Control Release, 74, 69–75 (2001).

Saravolac, E. G., Ludkovski, O., Skirrow, R., Ossanlou, M., Zhang, Y. P., Giesbrecht, C., Thompson, J., Thomas, S., Stark, H., Cullis, P. R., and Scherrer, P., Encapsulation of plasmid DNA in stabilized plasmid-lipid particles composed of different cationic lipid concentration for optimal transfection activity.J. Drug Target, 7, 423–437 (2000).

Schatzlein, A. G., Non-viral vectors in cancer gene therapy: principles and progress.Anti-Cancer Drugs, 12, 275–304 (2001).

Setoguchi, Y., Jaffe, H. A., Chu, C.-S., and Crystal, R. G., Intraperitonealin vivo gene therapy to deliver alpha 1-antitrypsin to the systemic circulation.Am. J. Resp. Cell. Mol. Biol., 10, 369–377 (1994).

Shi, N. and Pardridge, W. M., Noninvasive gene targeting to the brain.Proc. Natl. Acad. Sci. U.S.A., 97, 7567–7572 (2000).

Smith, T. A., Mehaffey, M. G., Kayda, D. B., Saunders, J. M., Yei, S., Trapnell, B. C., McClelland, A., and Kaleko, M., Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice.Nature Genet, 5, 397–402 (1993).

Stuart, D. D. and Allen, T. M., A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability.Biochim. Biophys. Acta, 1463, 219–229 (2000).

Worgall, S., Wolff, G., Falck-Pedersen, E., and Crystal, R. G., Innate immune mechanisms dominate elimination of adenoviral vectors followingin vivo administration.Hum. Gene Ther., 8, 37–44 (1997).

Yang, Y., Li, Q., Ertl, H. C., and Wilson, J. M., Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses.J. Virol., 69, 2004–2015 (1995a).

Yang, Y., Nunes, F. A., Berencsi, K., Furth, E. E., Gonczol, E., and Wilson, J. M., Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.Proc. Natl. Acad. Sci. U.S.A., 91, 4407–4411 (1995b).